• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

尼洛替尼治疗慢性髓性白血病导致肺动脉压升高。

Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.

机构信息

Department of Heart Valve Diseases, Institute of Cardiology, Warsaw, Poland.

出版信息

Int J Hematol. 2012 Jul;96(1):132-5. doi: 10.1007/s12185-012-1103-0. Epub 2012 May 26.

DOI:10.1007/s12185-012-1103-0
PMID:22639052
Abstract

We present the case of a 72-year-old male with chronic phase myeloid leukemia. Elevation of the pulmonary artery pressure due to nilotinib therapy was noted. This effect on pulmonary artery pressure was nilotinib dose dependent.

摘要

我们报告一例 72 岁男性慢性髓性白血病患者。因尼洛替尼治疗而出现肺动脉压升高。这种对肺动脉压的影响与尼洛替尼剂量有关。

相似文献

1
Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.尼洛替尼治疗慢性髓性白血病导致肺动脉压升高。
Int J Hematol. 2012 Jul;96(1):132-5. doi: 10.1007/s12185-012-1103-0. Epub 2012 May 26.
2
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.与达沙替尼治疗慢性粒细胞白血病相关的完全可逆性肺动脉高压。
Eur Respir J. 2011 Jul;38(1):218-20. doi: 10.1183/09031936.00154210.
3
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.可逆性肺动脉高压可能与长期低剂量达沙替尼治疗慢性髓性白血病有关。
Leuk Res. 2012 Jan;36(1):e4-6. doi: 10.1016/j.leukres.2011.08.007. Epub 2011 Sep 3.
4
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.一名慢性粒细胞白血病患者中继发于达沙替尼的可逆性重度肺动脉高压
Leuk Res. 2009 Jun;33(6):861-4. doi: 10.1016/j.leukres.2008.09.026. Epub 2008 Nov 4.
5
Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.伴有新型e8a1 BCR-ABL1融合的慢性髓性白血病：尼洛替尼治疗后的快速分子反应
Leuk Lymphoma. 2017 Sep;58(9):1-6. doi: 10.1080/10428194.2017.1281413. Epub 2017 Jan 25.
6
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.达沙替尼治疗慢性髓性白血病引起的肺动脉高压 - 严重警示 -
Intern Med. 2012;51(17):2337-40. doi: 10.2169/internalmedicine.51.7472. Epub 2012 Sep 1.
7
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.尼洛替尼与伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病患者：3 期随机 ENESTnd 试验的 24 个月最小随访。
Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.
8
Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.通过无创超声心动图诊断的可逆性达沙替尼相关肺动脉高压
Kaohsiung J Med Sci. 2015 Mar;31(3):165-6. doi: 10.1016/j.kjms.2014.11.010. Epub 2014 Dec 22.
9
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.尼洛替尼与伊马替尼相比，可降低新诊断的慢性期慢性髓性白血病患者的 BCR-ABL 突变发生率。
Blood. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. Epub 2013 Mar 15.
10
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.尼罗替尼（原AMN107）是一种高度选择性的BCR-ABL酪氨酸激酶抑制剂，对伊马替尼耐药和不耐受的慢性期费城染色体阳性慢性髓性白血病患者有效。
Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22.

引用本文的文献

1
A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.癌症药物诱导的血液系统恶性肿瘤患者心脏毒性的全面综述：当前观点与治疗策略。
Curr Treat Options Oncol. 2024 Apr;25(4):465-495. doi: 10.1007/s11864-023-01175-z. Epub 2024 Feb 19.
2
Differentiating pulmonary hypertension associated with protein kinase inhibitors.鉴别与蛋白激酶抑制剂相关的肺动脉高压
Pulm Circ. 2022 May 11;12(2):e12075. doi: 10.1002/pul2.12075. eCollection 2022 Apr.
3
Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.

本文引用的文献

1
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.可逆性肺动脉高压可能与长期低剂量达沙替尼治疗慢性髓性白血病有关。
Leuk Res. 2012 Jan;36(1):e4-6. doi: 10.1016/j.leukres.2011.08.007. Epub 2011 Sep 3.
2
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?多酪氨酸激酶抑制剂达沙替尼是否为严重前毛细血管性肺动脉高压的新病因？
BMC Pulm Med. 2011 May 23;11:30. doi: 10.1186/1471-2466-11-30.
3
Preclinical evaluation of potential nilotinib cardiotoxicity.
在慢性期慢性髓性白血病中，达沙替尼治疗后博舒替尼诱导的肺动脉高压复发，使用尼罗替尼成功治疗。
Leuk Res Rep. 2022 Apr 19;17:100312. doi: 10.1016/j.lrr.2022.100312. eCollection 2022.
4
EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors.快报：达沙替尼及其他酪氨酸激酶抑制剂所致肺动脉高压
Pulm Circ. 2019 Jul 5;9(3):2045894019865704. doi: 10.1177/2045894019865704.
5
Dasatinib-induced pulmonary arterial hypertension.达沙替尼致肺动脉高压。
Br J Clin Pharmacol. 2018 May;84(5):835-845. doi: 10.1111/bcp.13508. Epub 2018 Mar 6.
6
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?肺动脉高压治疗：今天我们在哪里，明天我们去哪里？
Eur Respir Rev. 2013 Sep 1;22(129):217-26. doi: 10.1183/09059180.00001713.
潜在尼洛替尼心脏毒性的临床前评估。
Leuk Res. 2011 May;35(5):631-7. doi: 10.1016/j.leukres.2010.11.001. Epub 2010 Dec 3.
4
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.伊马替尼治疗对既定疗法反应不足的肺动脉高压患者。
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7. doi: 10.1164/rccm.201001-0123OC. Epub 2010 Jun 25.
5
Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.在一名既往接受过同种异体移植的慢性粒细胞白血病患者中，达沙替尼诱发可逆性肺动脉高压和右心室衰竭。
Bone Marrow Transplant. 2009 Jun;43(12):967-8. doi: 10.1038/bmt.2008.415. Epub 2008 Dec 22.
6
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.一名慢性粒细胞白血病患者中继发于达沙替尼的可逆性重度肺动脉高压
Leuk Res. 2009 Jun;33(6):861-4. doi: 10.1016/j.leukres.2008.09.026. Epub 2008 Nov 4.
7
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.多靶点酪氨酸激酶抑制剂伊马替尼、达沙替尼、舒尼替尼和索拉非尼对分离的大鼠心脏线粒体及H9c2细胞线粒体功能的影响。
Toxicol Sci. 2008 Nov;106(1):153-61. doi: 10.1093/toxsci/kfn157. Epub 2008 Jul 29.
8
Possible role of imatinib in clinical pulmonary veno-occlusive disease.伊马替尼在临床肺静脉闭塞病中的可能作用。
Eur Respir J. 2008 Jul;32(1):232-5. doi: 10.1183/09031936.00054407.
9
An evaluation of the cardiotoxicity of imatinib mesylate.甲磺酸伊马替尼的心脏毒性评估。
Leuk Res. 2008 Dec;32(12):1809-14. doi: 10.1016/j.leukres.2008.03.020. Epub 2008 May 20.
10
Congestive heart failure is a rare event in patients receiving imatinib therapy.充血性心力衰竭在接受伊马替尼治疗的患者中是罕见事件。
Blood. 2007 Aug 15;110(4):1233-7. doi: 10.1182/blood-2007-01-070144. Epub 2007 Apr 20.